DE SOTO, Kan., April 29, 2014 – In recognition of his dedication to advancing technology and information sharing among bovine veterinarians, Roger Winter, D.V.M. has been awarded the Academy of Veterinary Consultants’ (AVC) 2014 Outstanding Service Award. An advocate of continuous learning and professional advancement, Dr. Winter has committed his time and talent to ensuring that all AVC members have access to seminars, presentations, research data and more, not only to further strengthen veterinarians’ expertise, but also to advance the U.S. beef cattle industry.
Sponsored by Merck Animal Health for the past nine years, the annual award recognizes an AVC member who has made exceptional contributions to the organization, as well as the beef cattle and veterinary medical professions. In support of the company’s long-standing commitment to honoring those who have made an indelible mark on the industry and supporting future leaders, Merck Animal Health also made a donation to the AVC Foundation in Dr. Winter’s honor.
Mark Spire, D.V.M., MS, D.A.C.T., technical services manager for Merck Animal Health and one of the award’s presenters, said, “Dr. Winter’s educational efforts are no small measure. In fact, they are at the very heart of the AVC mission of providing continuing education, member support and leadership.”
While Dr. Winter has spent more than 30 years serving beef producers both through private practice and as an allied industry technical service veterinarian, it is his unique service to AVC and his fellow veterinarians that has garnered this latest accolade. Six years ago, Dr. Winter organized the AVC audiovisual committee with the objective of making meeting proceedings, seminars, podcasts and other information on the website available to every AVC member. Much of this information has allowed AVC members to gain continuing-education credits, as well as remain up-to-date on bovine health and industry developments.
Also presenting the award was Kurt Walters, D.V.M., with the Buffalo Veterinary Clinic in Buffalo, Wyo., and a member of the AVC Board of Directors. “Dr. Winter’s efforts have allowed the academy to provide the best and most current continuing education in the beef industry. AVC is lucky to have such a talented and dedicated member.”
Jim Furman, D.V.M., and Tom Furman, D.V.M., with The Animal Center in Alliance, Neb., were two of several veterinarians who nominated Dr. Winter and explained: “Dr. Winter works tirelessly to improve the quality of audio and visuals, making them available for all AVC members within days of the meetings. This has provided extensive savings to AVC and is a tremendous value to his fellow veterinarians.”Dr. Winter earned his Doctor of Veterinary Medicine from Kansas State University College of Veterinary Medicine in 1981 and moved to western Kansas where he was in private practice for 13 years. For the past 20 years, he further expanded his industry experience by working for several different companies.
“I am humbled and honored to be recognized by my peers for work that I truly enjoy,” said Dr. Winter. “My reward has always come from sharing the wealth of knowledge between and among my fellow AVC members.”
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).